| Literature DB >> 26563250 |
Mirjam H Mastenbroek1,2, Susanne S Pedersen3,4,5, Mathias Meine1, Henneke Versteeg6,7.
Abstract
PURPOSE: It is well known that a significant proportion of heart failure patients (10-44 %) do not show improvement in symptoms or functioning from cardiac resynchronization therapy (CRT), yet no study has examined patient-reported health status trajectories after implantation.Entities:
Keywords: Cardiac resynchronization therapy; Health status; Heart failure; KCCQ; Trajectories
Mesh:
Year: 2015 PMID: 26563250 PMCID: PMC4870284 DOI: 10.1007/s11136-015-1176-3
Source DB: PubMed Journal: Qual Life Res ISSN: 0962-9343 Impact factor: 4.147
Identification of the number of latent classes for health status after CRT-D implantation
| Solution | Physical health status | Quality of life | Social limitation | ||||||
|---|---|---|---|---|---|---|---|---|---|
| LL | Npar | BIC | LL | Npar | BIC | LL | Npar | BIC | |
| 1 Class | −2334.13 | 5 | 4692.93 | −2367.98 | 5 | 4760.63 | −2359.51 | 5 | 4743.70 |
| 2 Classes | −2212.71 | 11 | 4479.69 | −2286.94 | 11 | 4628.16 | −2255.51 | 11 | 4565.29 |
| 3 Classes | −2176.28 | 17 | 4436.44 | −2259.92 | 17 | 4603.73 | −2217.67 | 17 | 4519.24 |
| 4 Classes | −2152.69 | 23 | 4418.87 | −2239.63 | 23 | 4592.75 | − |
|
|
|
| − |
|
| − |
|
| −2177.38 |
| 4497.87 |
| 6 Classes | −2124.26 | 35 | 4421.23 | −2210.51 | 35 | 4593.72 | −2166.43 | 35 | 4505.57 |
| 7 Classes | −2112.40 | 41 | 4427.12 | −2197.05 | 41 | 4596.41 | −2153.72 | 41 | 4509.76 |
| 8 Classes | −2103.08 | 47 | 4438.08 | −2184.38 | 47 | 4600.68 | −2145.69 | 47 | 4523.31 |
LL log likelihood; Npar number of parameters; BIC Bayesian information criterion
The selected number of classes is marked in bold for each outcome
Fig. 1a–c Trajectories of physical health status, quality of life, and social limitation after CRT-D implantation
Baseline characteristics stratified by physical health status trajectories after CRT-D implantation*
| Baseline variable | Missing | Total | Excellent | Fairly good–Excellent | Good | Poor–Good | Poor |
|
|---|---|---|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | ( | ( | ||
|
| ||||||||
| Mean age (SD) | 0 (0) | 65.7 (10.1) | 68.0 (9.9) | 63.4 (12.7) | 64.8 (11.3) | 64.8 (7.9) | 66.8 (9.6) | .64 |
| Male gender | 0 (0) | 97 (70) | 16 (89) | 10 (71) | 30 (79) | 13 (46) | 28 (68) | .019 |
| Having a partner | 0 (0) | 113 (81) | 17 (94) | 12 (86) | 32 (84) | 22 (79) | 30 (73) | .45 |
| Low education‡ | 1 (1) | 18 (13) | 0 (0) | 1 (7) | 1 (3) | 7 (25) | 9 (23) |
|
| Being employed | 1 (1) | 30 (22) | 5 (28) | 4 (29) | 11 (29) | 2 (7) | 8 (20) | .51 |
|
| ||||||||
| Upgrade§ | 0 (0) | 36 (26) | 5 (28) | 4 (29) | 9 (24) | 7 (25) | 11 (27) | .98 |
| ICD as sec. prevention | 0 (0) | 26 (19) | 7 (39) | 2 (15) | 5 (13) | 6 (21) | 6 (15) | .34 |
| Ischemic etiology | 0 (0) | 68 (49) | 10 (56) | 3 (21) | 20 (53) | 13 (46) | 22 (54) | .29 |
| NYHA class III/IV | 0 (0) | 110 (79) | 6 (33) | 10 (71) | 28 (74) | 28 (100) | 38 (93) |
|
| Mean LVEF (SD) | 6 (4) | 24.9 (8.6) | 27.1 (10.2) | 23.2 (7.7) | 24.2 (8.7) | 26.2 (8.6) | 24.4 (8.2) | .74 |
| Mean QRS (SD) | 11 (8) | 162 (25) | 163 (24) | 166 (22) | 162 (28) | 165 (26) | 160 (24) | .92 |
| LBBB | 28 (20) | 60 (54) | 8 (50) | 8 (73) | 17 (50) | 14 (61) | 13 (48) | .51 |
| ESV responder|| | 25 (18) | 61 (54) | 10 (63) | 7 (58) | 23 (66) | 10 (46) | 11 (38) | .40 |
| Comorbidity# | 6 (4) | 79 (59) | 8 (47) | 4 (31) | 24 (63) | 17 (63) | 26 (68) | .55 |
| ICD shock | 18 (13) | 11 (9) | 0 (0) | 1 (8) | 6 (17) | 0 (0) | 4 (13) |
|
| Smoking | 0 (0) | 21 (15) | 1 (6) | 1 (7) | 5 (13) | 7 (25) | 7 (17) | .43 |
|
| ||||||||
| Amiodarone | 0 (0) | 17 (12) | 4 (22) | 2 (14) | 3 (8) | 1 (4) | 7 (17) | .38 |
| ACE inhibitors | 0 (0) | 126 (91) | 16 (89) | 11 (79) | 36 (95) | 25 (89) | 38 (93) | .58 |
| Beta-blockers | 0 (0) | 108 (78) | 15 (83) | 10 (71) | 31 (82) | 23 (82) | 29 (71) | .60 |
| Statins | 0 (0) | 84 (60) | 14 (78) | 3 (21) | 20 (53) | 19 (68) | 28 (68) | .018 |
| Psychotropic medication | 0 (0) | 33 (24) | 1 (6) | 1 (7) | 6 (16) | 9 (32) | 16 (39) | .041 |
|
| ||||||||
| Anxiety (STAI-S ≥ 40) | 2 (1) | 59 (43) | 2 (11) | 3 (21) | 12 (32) | 17 (61) | 25 (63) | .001 |
| Depression (PHQ-9 ≥ 10) | 1 (1) | 32 (23) | 0 (0) | 2 (14) | 1 (3) | 8 (29) | 21 (51) |
|
| Type D personality | 1 (1) | 32 (23) | 1 (6) | 1 (8) | 8 (21) | 8 (29) | 14 (34) | .13 |
ACE angiotensin-converting enzyme; ESV end-systolic volume; ICD implantable cardioverter-defibrillator; LBBB left bundle branch block; NYHA New York Heart Association; SD standard deviation; sec. secondary
* Results are presented as n (%), unless otherwise indicated. Significant results are printed in bold (Bonferroni’s corrected p value = 0.05/72 = 6.9e−4)
† p values were obtained using adjusted Step-3-Dependent analysis procedures in Latent GOLD 5.0. All other values were observed values obtained using SPSS
‡Defined as primary education versus secondary education and higher
§Upgrade from another implantable device, either (biventricular) pacemaker or ICD without cardiac resynchronization therapy
||Echocardiographic response was defined as a decrease in left ventricular end-systolic volume of ≥15 % measured at 6-month follow-up
#Comorbidity = atrial fibrillation, chronic obstructive pulmonary disease, diabetes, or renal failure
Baseline characteristics stratified by quality of life trajectories after CRT-D implantation*
| Baseline variable | Missing | Total | Excellent | Fairly good–Very good | Adequate | Very poor–Good | Poor |
|
|---|---|---|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | ( | ( | ||
|
| ||||||||
| Mean age (SD) | 0 (0) | 65.7 (10.1) | 68.1 (9.9) | 67.1 (10.0) | 63.8 (10.8) | 64.7 (8.8) | 67.1 (9.9) | .79 |
| Male gender | 0 (0) | 97 (70) | 7 (78) | 31 (74) | 36 (72) | 10 (56) | 13 (65) | .50 |
| Having a partner | 0 (0) | 113 (81) | 8 (89) | 36 (86) | 39 (78) | 16 (89) | 14 (70) | .57 |
| Low education‡ | 1 (1) | 18 (13) | 0 (0) | 2 (5) | 5 (10) | 6 (33) | 5 (26) |
|
| Being employed | 1 (1) | 30 (22) | 2 (22) | 7 (17) | 16 (33) | 3 (17) | 2 (10) | .24 |
|
| ||||||||
| Upgrade§ | 0 (0) | 36 (26) | 2 (22) | 11 (26) | 15 (30) | 1 (6) | 7 (35) | .13 |
| ICD as sec. prevention | 0 (0) | 26 (19) | 3 (33) | 8 (19) | 8 (16) | 2 (11) | 5 (25) | .44 |
| Ischemic etiology | 0 (0) | 68 (49) | 6 (67) | 18 (43) | 26 (52) | 9 (50) | 9 (45) | .76 |
| NYHA class III/IV | 0 (0) | 110 (79) | 2 (22) | 28 (67) | 45 (90) | 17 (94) | 18 (90) | .001 |
| Mean LVEF (SD) | 6 (4) | 24.9 (8.6) | 28.2 (11.3) | 24.7 (8.5) | 24.4 (9.0) | 25.1 (7.9) | 25.2 (7.5) | .98 |
| Mean QRS (SD) | 11 (8) | 162 (25) | 156 (20) | 168 (26) | 160 (26) | 161 (22) | 162 (26) | .39 |
| LBBB | 28 (20) | 60 (54) | 5 (56) | 21 (58) | 18 (45) | 10 (71) | 6 (50) | .53 |
| ESV responder|| | 25 (18) | 61 (54) | 6 (67) | 20 (54) | 21 (50) | 10 (71) | 4 (33) | .44 |
| Comorbidity# | 6 (4) | 79 (59) | 4 (44) | 24 (60) | 28 (58) | 10 (59) | 13 (68) | .92 |
| ICD shock | 18 (13) | 11 (9) | 0 (0) | 2 (5) | 7 (16) | 1 (7) | 1 (7) | .009 |
| Smoking | 0 (0) | 21 (15) | 0 (0) | 5 (12) | 7 (14) | 6 (33) | 3 (15) |
|
|
| ||||||||
| Amiodarone | 0 (0) | 17 (12) | 2 (22) | 5 (12) | 4 (8) | 0 (0) | 6 (30) |
|
| ACE inhibitors | 0 (0) | 126 (91) | 9 (100) | 36 (86) | 47 (94) | 16 (89) | 18 (90) | .021 |
| Beta-blockers | 0 (0) | 108 (78) | 9 (100) | 33 (79) | 42 (84) | 12 (67) | 12 (60) |
|
| Statins | 0 (0) | 84 (60) | 6 (67) | 24 (57) | 32 (64) | 10 (56) | 12 (60) | .97 |
| Psychotropic medication | 0 (0) | 33 (24) | 0 (0) | 6 (14) | 16 (32) | 3 (17) | 8 (40) |
|
|
| ||||||||
| Anxiety (STAI-S ≥ 40) | 2 (1) | 59 (43) | 1 (11) | 10 (24) | 22 (45) | 12 (71) | 14 (70) |
|
| Depression (PHQ-9 ≥ 10) | 1 (1) | 32 (23) | 0 (0) | 0 (0 | 13 (26) | 8 (44) | 11 (55) |
|
| Type D personality | 1 (1) | 32 (23) | 0 (0) | 6 (14) | 10 (20) | 7 (39) | 9 (45) |
|
ACE angiotensin-converting enzyme; ESV end-systolic volume; ICD implantable cardioverter-defibrillator; LBBB left bundle branch block; NYHA New York Heart Association; SD standard deviation; sec. secondary
* Results are presented as n (%), unless otherwise indicated. Significant results are printed in bold (Bonferroni’s corrected p value = 0.05/72 = 6.9e−4)
† p values were obtained using adjusted Step-3-Dependent analysis procedures in Latent GOLD 5.0. All other values were observed values obtained using SPSS
‡Defined as primary education versus secondary education and higher
§Upgrade from another implantable device, either (biventricular) pacemaker or ICD without cardiac resynchronization therapy
||Echocardiographic response was defined as a decrease in left ventricular end-systolic volume of ≥15 % measured at 6-month follow-up
#Comorbidity = atrial fibrillation, chronic obstructive pulmonary disease, diabetes, or renal failure
Baseline characteristics stratified by social limitation trajectories after CRT-D implantation*
| Baseline variable | Missing | Total | Very good–Excellent | Adequate–Very good | Moderate–Adequate | Very poor |
|
|---|---|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | ( | ||
|
| |||||||
| Mean age (SD) | 0 (0) | 65.7 (10.1) | 64.1 (10.7) | 66.9 (8.8) | 65.3 (10.8) | 66.4 (10.5) | .89 |
| Male gender | 0 (0) | 97 (70) | 15 (71) | 26 (63) | 48 (73) | 8 (73) | .64 |
| Having a partner | 0 (0) | 113 (81) | 19 (91) | 34 (83) | 53 (80) | 7 (64) | .46 |
| Low education‡ | 1 (1) | 18 (13) | 2 (10) | 2 (5) | 12 (19) | 2 (18) | .30 |
| Being employed | 1 (1) | 30 (22) | 6 (29) | 9 (23) | 13 (20) | 2 (18) | .74 |
|
| |||||||
| Upgrade§ | 0 (0) | 36 (26) | 4 (19) | 13 (32) | 16 (24) | 3 (27) | .79 |
| ICD as sec. prevention | 0 (0) | 26 (19) | 7 (33) | 6 (15) | 9 (14) | 4 (36) | .05 |
| Ischemic etiology | 0 (0) | 68 (49) | 13 (62) | 14 (34) | 36 (55) | 5 (46) | .15 |
| NYHA class III/IV | 0 (0) | 110 (79) | 8 (38) | 32 (78) | 61 (92) | 9 (82) |
|
| Mean LVEF (SD) | 6 (4) | 24.9 (8.6) | 28.3 (9.7) | 23.9 (7.9) | 24.5 (8.6) | 24.8 (8.7) | .38 |
| Mean QRS (SD) | 11 (8) | 162 (25) | 162 (27) | 168 (26) | 160 (23) | 158 (27) | .82 |
| LBBB | 28 (20) | 60 (54) | 12 (63) | 21 (58) | 24 (49) | 3 (43) | .53 |
| ESV responder|| | 25 (18) | 61 (54) | 12 (63) | 21 (57) | 27 (53) | 1 (14) | .40 |
| Comorbidity# | 6 (4) | 79 (59) | 8 (38) | 23 (59) | 43 (69) | 5 (46) | .08 |
| ICD shock | 18 (13) | 11 (9) | 0 (0) | 2 (5) | 9 (17) | 0 (0) |
|
| Smoking | 0 (0) | 21 (15) | 1 (5) | 6 (15) | 12 (18) | 2 (18) | .50 |
|
| |||||||
| Amiodarone | 0 (0) | 17 (12) | 3 (14) | 3 (7) | 6 (9) | 5 (46) | .032 |
| ACE inhibitors | 0 (0) | 126 (91) | 17 (81) | 38 (93) | 60 (91) | 11 (100) | .40 |
| Beta-blockers | 0 (0) | 108 (78) | 18 (86) | 32 (78) | 53 (80) | 5 (46) | .046 |
| Statins | 0 (0) | 84 (60) | 14 (67) | 24 (59) | 39 (59) | 7 (64) | .94 |
| Psychotropic medication | 0 (0) | 33 (24) | 0 (0) | 5 (12) | 24 (36) | 4 (36) |
|
|
| |||||||
| Anxiety (STAI-S ≥ 40) | 2 (1) | 59 (43) | 4 (19) | 16 (36) | 31 (48) | 8 (73) | .031 |
| Depression (PHQ-9 ≥ 10) | 1 (1) | 32 (23) | 1 (5) | 3 (7) | 22 (33) | 6 (55) | .002 |
| Type D personality | 1 (1) | 32 (23) | 2 (10) | 7 (17) | 19 (29) | 4 (36) | .12 |
ACE angiotensin-converting enzyme; ESV end-systolic volume; ICD implantable cardioverter-defibrillator; LBBB left bundle branch block; NYHA New York Heart Association; SD standard deviation; sec. secondary
* Results are presented as n (%), unless otherwise indicated. Significant results are printed in bold (Bonferroni’s corrected p value = 0.05/72 = 6.9e−4)
† p values were obtained using adjusted Step-3-Dependent analysis procedures in Latent GOLD 5.0. All other values were observed values obtained using SPSS
‡Defined as primary education versus secondary education and higher
§Upgrade from another implantable device, either (biventricular) pacemaker or ICD without cardiac resynchronization therapy
||Echocardiographic response was defined as a decrease in left ventricular end-systolic volume of ≥15 % measured at 6-month follow-up
#Comorbidity = atrial fibrillation, chronic obstructive pulmonary disease, diabetes, or renal failure